Figure 3.

Proteomic pathway-based stratification of the patients with PCa associated with their prognosis

(A) The heatmap shows the normalized enrichment scores of the three patient subtypes (CPC1, N = 126; CPC2, N = 57; and CPC3, N = 43) using NMF analysis. The associations of proteomic subtypes with clinical characteristics (pathological stages, PSA, biochemical recurrence [BCR], and ISUP grade) are annotated.

(B) Kaplan-Meier curves of the BCR-free survival of each patient subtype from our cohort (log rank p = 0.0012).

(C) Distribution of the clinical indexes in the three patient subtypes.

(D) Relative expression of the dysregulated druggable proteins in the three patient subtypes. One-way ANOVA, B-H adjusted p value: ∗ < 0.05; ∗∗ < 0.01; ∗∗∗ < 0.001; ∗∗∗∗ < 0.0001. BE, preoperative endocrine therapy; PE, postoperative endocrine therapy; PR, postoperative radiotherapy.

See also Figure S2.